论文部分内容阅读
目的 :研究新辅助化疗联合保乳手术治疗Ⅱ、Ⅲ期乳腺癌的临床疗效。方法 :回顾性分析我院100例粗针穿刺确诊乳腺癌的患者。采用TAC进行新辅助化疗,每3周重复一次,化疗4~6周期,对PR、CR患者行肿瘤局部广泛切除术和腋窝淋巴结清扫术,术后常规辅助内分泌治疗、放化疗,统计分析患者临床疗效。结果:新辅助化疗患者有效率为73%(73/100),63例成功施行保乳手术,保乳率63%(63/100)。保乳患者随访39月~50月,局部复发8例,远处转移7例。结论 :新辅助化疗对Ⅱ、Ⅲ期乳腺癌患者降期后,无明显手术禁忌症下,可实施保乳手术,疗效可靠。
Objective: To study the clinical efficacy of neoadjuvant chemotherapy combined with breast-conserving surgery for stage II and III breast cancer. Methods: Retrospective analysis of 100 patients with confirmed breast cancer in our hospital. Neoadjuvant chemotherapy was performed with TAC every 3 weeks. Chemotherapy was performed for 4 to 6 cycles. Patients with PR and CR underwent extensive local tumor resection and axillary lymph node dissection. Postoperative routine adjuvant endocrine therapy, radiotherapy and chemotherapy, and statistical analysis of patients’ clinical Efficacy. RESULTS: The effective rate of neoadjuvant chemotherapy was 73% (73/100). 63 cases were successfully breast-conserved and the rate of breast-conserving was 63% (63/100). The follow-up of breast-conserving patients ranged from 39 months to 50 months, with 8 cases of local recurrence and 7 cases of distant metastases. Conclusion: Neoadjuvant chemotherapy can be used for breast-conserving surgery in patients with stage II and stage III breast cancer after declining and without obvious surgical contraindications. The curative effect is reliable.